ANALYST VIEW - Jefferies raises target price for Hungary's Richter

Portfolio
After the release of Richter’s third-quarter earnings report, Jefferies has raised its target price for Hungary’s leading pharmaceutical producer to HUF 7,890 from HUF 7,470 previously. The rating remains ‘Buy’.
Key takeaway:
  • On robust 9M figures, with a guidance raise driven by Vraylar and cost control, Jefferies has raised its earnings per share (EPS) estimate by 5-6% on an u/l basis and increased its target price to HUF 7,890 from HUF 7,470 previously.
  • Jefferies still expects buyside cons to be more cautious until visibility improves which is the buying opportunity as it believe the mid-term story remains intact. Jefferies has retain its ‘Buy’ recommendation as Richter is its preferred name in EMEA generics.
  • Jefferies noted that Vraylar royalties were robust (USD 35.9 mn at 9M), driven by continued uptake and things are “looking good for the rest of the year". Esmya growth was also above its expectations, with sales at EUR 67.5 mn at 9M (+40%) and guidance was raised for the year.
  • Growth was mainly in the EU15 region, though additional launches and its expanded use in the long-term management of uterine fibroids also had a benefit. As a reminder, the US filing for Esmya was accepted on Oct 10 and we anticipate approval 1H ‘18E which Jefferies believes would be a boost for the stock. On Biosimilars, Richter anticipates to refile pegfilgrastim in 1Q.
  • EBIT margin guidance was also raised, and Jefferies expects GM expansion next year: Although GM’s were sequentially flat despite higher royalties, it noted pricing pressure, 1H FX headwinds, higher amortization (Esmya & Bemfola) and an impact due to inventories on Bemfola profitability all had an impact. Going forward, Richter affirmed that the mix should shift to higher margin products which Jefferies would view favourably, allowing its bull thesis to play out.
  • Jefferies also noted that Richter’s net cash position gives the group significant strategic flexibility. It forecasts EUR 237 mn net cash by end 2017.
  • Although the dividend payout is unlikely to go >30%, (raised last year from 25%), Jefferies expects cash to be prioritised for product deals across women’s healthcare or other deals which bolster its biosimilar and specialty pharma credentials.


As regards the risks, Jefferies listed the following: Esmya fails to achieve US approval, Vraylar begins to disappoint, CIS declines, FX volatility, a more rapid decline in US base business.

' title='
 

More in Equity

tőzsde-kriptovaluta-bitcoin-befektetés-short-squeeze
July 10, 2025 16:25

Crypto enthusiasts launch petition against new 'outrageous' Hungarian rules

They are speaking out against the "criminalisation" of cryptocurrency investments

Súlyos büntetéssel fenyegetik a Wizz Airt, indul az eljárás
July 10, 2025 08:52

Fitch Ratings downgrades Wizz Air

Due to weaker-than-expected annual performance and other factors

revolut shutter
July 08, 2025 10:25

Revolut freezes the sale of cryptocurrencies for its Hungarian customers

Neobank sends new information

GettyImages-2202706663
July 07, 2025 08:00

Revolut bans most cryptocurrency transactions for Hungarian customers with immediate effect

Recent legislative changes have led the operator to take action

otp bankfiók belső és külső képek, logó
July 02, 2025 08:17

The current economic environment in Hungary is not favourable - OTP CEO

OTP is producing solid results thanks to its international presence

June 26, 2025 13:58

MTel EGM decides to separate passive mobile infrastructure

As of 31 October

LATEST NEWS

Detailed search